News stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.5283142675977 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.26 Million (americanbankingnews.com)
- Tetraphase Pharmaceuticals Inc (TTPH) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- -$0.64 Earnings Per Share Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter (americanbankingnews.com)
- Tetraphase Pharmaceuticals (TTPH) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Jacques Dumas Sells 7,167 Shares of Tetraphase Pharmaceuticals Inc (TTPH) Stock (americanbankingnews.com)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $0.02 during mid-day trading on Thursday, hitting $6.24. The stock had a trading volume of 256,900 shares, compared to its average volume of 430,391. The company has a market capitalization of $321.86, a P/E ratio of -2.18 and a beta of 2.51. Tetraphase Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.93.
A number of equities analysts have commented on the company. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. HC Wainwright boosted their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Finally, BMO Capital Markets boosted their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.15.
In related news, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total value of $44,507.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Earning Somewhat Positive Press Coverage, Accern Reports” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/01/18/tetraphase-pharmaceuticals-ttph-earning-somewhat-positive-press-coverage-accern-reports.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.